Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Shares Bought by FARMERS & MERCHANTS TRUST Co OF LONG BEACH

FARMERS & MERCHANTS TRUST Co OF LONG BEACH raised its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 4.4% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 10,268 shares of the medical equipment provider’s stock after acquiring an additional 430 shares during the quarter. FARMERS & MERCHANTS TRUST Co OF LONG BEACH’s holdings in Zimmer Biomet were worth $1,355,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of ZBH. O Shaughnessy Asset Management LLC grew its position in Zimmer Biomet by 19.0% in the third quarter. O Shaughnessy Asset Management LLC now owns 12,044 shares of the medical equipment provider’s stock valued at $1,352,000 after acquiring an additional 1,923 shares in the last quarter. Tower Research Capital LLC TRC grew its position in shares of Zimmer Biomet by 8.4% during the third quarter. Tower Research Capital LLC TRC now owns 8,558 shares of the medical equipment provider’s stock worth $960,000 after buying an additional 662 shares in the last quarter. Ancora Advisors LLC grew its position in shares of Zimmer Biomet by 63.3% during the third quarter. Ancora Advisors LLC now owns 570 shares of the medical equipment provider’s stock worth $64,000 after buying an additional 221 shares in the last quarter. Gotham Asset Management LLC grew its position in shares of Zimmer Biomet by 1.6% during the third quarter. Gotham Asset Management LLC now owns 44,105 shares of the medical equipment provider’s stock worth $4,949,000 after buying an additional 706 shares in the last quarter. Finally, Schonfeld Strategic Advisors LLC grew its position in shares of Zimmer Biomet by 91.6% during the third quarter. Schonfeld Strategic Advisors LLC now owns 119,990 shares of the medical equipment provider’s stock worth $13,465,000 after buying an additional 57,377 shares in the last quarter. Institutional investors and hedge funds own 88.89% of the company’s stock.

Zimmer Biomet Stock Performance

ZBH stock traded down $0.39 during mid-day trading on Tuesday, reaching $105.57. The company had a trading volume of 275,274 shares, compared to its average volume of 1,500,012. The company has a quick ratio of 0.80, a current ratio of 1.66 and a debt-to-equity ratio of 0.38. The stock has a market capitalization of $21.72 billion, a P/E ratio of 22.94, a P/E/G ratio of 1.95 and a beta of 1.01. Zimmer Biomet Holdings, Inc. has a one year low of $102.00 and a one year high of $144.80. The stock’s 50-day simple moving average is $115.29 and its two-hundred day simple moving average is $121.22.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings data on Thursday, May 2nd. The medical equipment provider reported $1.94 earnings per share for the quarter, topping the consensus estimate of $1.87 by $0.07. The business had revenue of $1.89 billion during the quarter, compared to the consensus estimate of $1.87 billion. Zimmer Biomet had a net margin of 12.93% and a return on equity of 12.70%. The company’s quarterly revenue was up 3.2% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.89 earnings per share. Research analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.1 EPS for the current year.

Zimmer Biomet Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, July 31st. Shareholders of record on Wednesday, June 26th will be given a $0.24 dividend. This represents a $0.96 annualized dividend and a yield of 0.91%. The ex-dividend date is Wednesday, June 26th. Zimmer Biomet’s dividend payout ratio (DPR) is presently 20.78%.

Analyst Upgrades and Downgrades

ZBH has been the subject of a number of recent analyst reports. Oppenheimer raised their price target on shares of Zimmer Biomet from $150.00 to $155.00 and gave the stock an “outperform” rating in a research report on Friday, May 3rd. Citigroup raised their price target on shares of Zimmer Biomet from $134.00 to $140.00 and gave the stock a “neutral” rating in a research report on Wednesday, April 3rd. The Goldman Sachs Group started coverage on Zimmer Biomet in a research note on Thursday, May 30th. They set a “neutral” rating and a $129.00 price objective on the stock. Truist Financial reduced their price objective on Zimmer Biomet from $137.00 to $130.00 and set a “hold” rating on the stock in a research note on Friday, May 3rd. Finally, Piper Sandler cut Zimmer Biomet from an “overweight” rating to a “neutral” rating and reduced their price objective for the stock from $140.00 to $115.00 in a research note on Monday. One research analyst has rated the stock with a sell rating, ten have issued a hold rating and seven have given a buy rating to the company. According to MarketBeat.com, Zimmer Biomet has an average rating of “Hold” and an average price target of $132.65.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.